Literature DB >> 22890109

The gut microbiota-a clinical perspective on lessons learned.

Fergus Shanahan1.   

Abstract

Once considered obscure and largely ignored by microbiologists, the human microbiota has moved centre-stage in biology. The gut microbiota is now a focus of disparate research disciplines, with its contributions to health and disease ready for translation to clinical medicine. The changing composition of the microbiota is linked with changes in human behaviour and the rising prevalence of immunoallergic and metabolic disorders. The microbiota is both a target for drug therapy and a repository for drug discovery. Its secrets promise the realization of personalized medicine and nutrition, and will change and improve conventional dietary management.

Entities:  

Mesh:

Year:  2012        PMID: 22890109     DOI: 10.1038/nrgastro.2012.145

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN: 1759-5045            Impact factor:   46.802


  36 in total

1.  Beyond pattern recognition: five immune checkpoints for scaling the microbial threat.

Authors:  J Magarian Blander; Leif E Sander
Journal:  Nat Rev Immunol       Date:  2012-02-24       Impact factor: 53.106

2.  Antibiotics: Recover the lost art of drug discovery.

Authors:  Kim Lewis
Journal:  Nature       Date:  2012-05-23       Impact factor: 49.962

3.  Treatment of colitis with a commensal gut bacterium engineered to secrete human TGF-β1 under the control of dietary xylan 1.

Authors:  Zaed Z R Hamady; Nigel Scott; Mark D Farrar; Meenu Wadhwa; Paula Dilger; Terence R Whitehead; Robin Thorpe; Keith T Holland; J Peter A Lodge; Simon R Carding
Journal:  Inflamm Bowel Dis       Date:  2010-12-17       Impact factor: 5.325

Review 4.  Disorders of a modern lifestyle: reconciling the epidemiology of inflammatory bowel diseases.

Authors:  Charles N Bernstein; Fergus Shanahan
Journal:  Gut       Date:  2008-05-30       Impact factor: 23.059

5.  Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection.

Authors:  Matthew J Hamilton; Alexa R Weingarden; Michael J Sadowsky; Alexander Khoruts
Journal:  Am J Gastroenterol       Date:  2012-01-31       Impact factor: 10.864

6.  Anti-inflammatory capacity of selected lactobacilli in experimental colitis is driven by NOD2-mediated recognition of a specific peptidoglycan-derived muropeptide.

Authors:  Elise Macho Fernandez; Elise Macho Fernandez; Véronique Valenti; Christoph Rockel; Corinna Hermann; Bruno Pot; Ivo Gomperts Boneca; Corinne Grangette
Journal:  Gut       Date:  2011-04-06       Impact factor: 23.059

7.  Metabolic activity of the enteric microbiota influences the fatty acid composition of murine and porcine liver and adipose tissues.

Authors:  Rebecca Wall; R Paul Ross; Fergus Shanahan; Liam O'Mahony; Caitlin O'Mahony; Mairead Coakley; Orla Hart; Peadar Lawlor; Eamonn M Quigley; Barry Kiely; Gerald F Fitzgerald; Catherine Stanton
Journal:  Am J Clin Nutr       Date:  2009-04-08       Impact factor: 7.045

Review 8.  Gut microbes: from bugs to drugs.

Authors:  Fergus Shanahan
Journal:  Am J Gastroenterol       Date:  2010-01-12       Impact factor: 10.864

9.  Epidemiologic analysis of Crohn disease in Japan: increased dietary intake of n-6 polyunsaturated fatty acids and animal protein relates to the increased incidence of Crohn disease in Japan.

Authors:  R Shoda; K Matsueda; S Yamato; N Umeda
Journal:  Am J Clin Nutr       Date:  1996-05       Impact factor: 7.045

10.  Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity.

Authors:  Jorge Henao-Mejia; Eran Elinav; Chengcheng Jin; Liming Hao; Wajahat Z Mehal; Till Strowig; Christoph A Thaiss; Andrew L Kau; Stephanie C Eisenbarth; Michael J Jurczak; Joao-Paulo Camporez; Gerald I Shulman; Jeffrey I Gordon; Hal M Hoffman; Richard A Flavell
Journal:  Nature       Date:  2012-02-01       Impact factor: 49.962

View more
  34 in total

1.  Metabolomics technology and bioinformatics for precision medicine.

Authors:  Rajeev K Azad; Vladimir Shulaev
Journal:  Brief Bioinform       Date:  2019-11-27       Impact factor: 11.622

Review 2.  The Microbiome in Visceral Medicine: Inflammatory Bowel Disease, Obesity and Beyond.

Authors:  Mircea T Chiriac; Mousumi Mahapatro; Markus F Neurath; Christoph Becker
Journal:  Visc Med       Date:  2017-04-07

3.  Host-microbe interactions and spatial variation of cancer in the gut.

Authors:  Fergus Shanahan; Paul W O'Toole
Journal:  Nat Rev Cancer       Date:  2014-08       Impact factor: 60.716

4.  Gastrointestinal hormones and the dialogue between gut and brain.

Authors:  Graham J Dockray
Journal:  J Physiol       Date:  2014-02-24       Impact factor: 5.182

5.  Genomics of schizophrenia: time to consider the gut microbiome?

Authors:  T G Dinan; Y E Borre; J F Cryan
Journal:  Mol Psychiatry       Date:  2014-10-07       Impact factor: 15.992

Review 6.  Why is initial bacterial colonization of the intestine important to infants' and children's health?

Authors:  Pearl D Houghteling; W Allan Walker
Journal:  J Pediatr Gastroenterol Nutr       Date:  2015-03       Impact factor: 2.839

Review 7.  The intestinal microbiome, barrier function, and immune system in inflammatory bowel disease: a tripartite pathophysiological circuit with implications for new therapeutic directions.

Authors:  Stephen M Vindigni; Timothy L Zisman; David L Suskind; Christopher J Damman
Journal:  Therap Adv Gastroenterol       Date:  2016-04-19       Impact factor: 4.409

Review 8.  Integrative Physiology: At the Crossroads of Nutrition, Microbiota, Animal Physiology, and Human Health.

Authors:  François Leulier; Lesley T MacNeil; Won-Jae Lee; John F Rawls; Patrice D Cani; Martin Schwarzer; Liping Zhao; Stephen J Simpson
Journal:  Cell Metab       Date:  2017-03-07       Impact factor: 27.287

Review 9.  Commensal bacteria modulate the tumor microenvironment.

Authors:  Theofilos Poutahidis; Susan E Erdman
Journal:  Cancer Lett       Date:  2015-12-29       Impact factor: 8.679

Review 10.  The human microbiome is a source of therapeutic drug targets.

Authors:  Bret D Wallace; Matthew R Redinbo
Journal:  Curr Opin Chem Biol       Date:  2013-05-13       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.